INTRODUCTION
The growing obesity epidemic in both developed and developing countries is a global health problem. In 2013, 2.1 billion 29 of the world population people were categorized as overweight or obese, an increase of 27.5 in adults and 47.1 in children from 1980 to 2013 1 . Analysis of 97 studies including 2.88 million people revealed that obesity with a body mass index BMI of 35 kg/m 2 or higher is associated with significantly higher all-cause mortality than non-obesity BMI 25 kg/m 2 . A BMI of 25 to 35 kg/ m 2 , however, is not associated with higher mortality 2 . On the other hand, a study of 6292 individuals found that higher visceral fat area VFA is more strongly associated with the clustering of metabolic risk factors, such as hypertension, high blood glucose, high triglyceride, and low highdensity lipoprotein than higher subcutaneous fat, waist cir-structural characteristics were thought to induce these physiologic effects. Alpha-linolenic acid ALA is easier to burn by the body than palmitic, stearic, oleic, or linoleic acid based on studies in rodents 17, 18 and humans 19 . Therefore, DAG containing ALA ALA-DAG is expected to induce fat utilization as energy and is less likely to be stored as body fat. Thus, this study was performed to investigate the suppressive effects of 12-wk ALA-DAG consumption on VFA in obese people.
EXPERIMENTAL PROCEDURES 2.1 Ethics and management
This study was performed in accordance with the Declaration of Helsinki 2013 and was approved by the Ethics Review Board of the Miyawaki Orthopedic Hospital. After receiving a full explanation of the study, all participants provided written informed consent. The study was conducted at the Fukuhara Clinic Hokkaido, Japan under the supervision of the physicians in charge and managed by a contract research organization, New Drug Research Center, Inc. Tokyo, Japan . The study protocol was registered at the University Hospital Medical Information Network UMIN-CTR, http://www.umin.ac.jp/ctr/index-j.htm prior to inclusion of the first subject UMIN No. 000017864 .
Design and protocol
This was a randomized, double-blind controlled, parallelgroup designed study with a 12-wk treatment period and a subsequent 4-wk non-treatment period. Changes in VFA as the primary outcome were measured in all subjects during the consumption of 2.5 g/d of control TAG rapeseed oil or ALA-DAG containing 0.89 g/d DAG-bound ALA in addition to their daily diet for 12 wk. Secondary outcomes were changes in body weight, waist circumference, and safety parameters. Subjects were instructed to incorporate the test food into their daily diet breakfast, lunch, or dinner and not to consume between meals. Based on dietary records for the 3 d before the measurements, the amounts of nutrients consumed were analyzed. The subjects were instructed to limit their alcohol consumption to less than 30 g/d and to maintain their usual exercise habits during the study. To confirm their physical activity level, the subjects recorded their number of daily steps measured using a pedometer.
Subjects
Potential subjects were recruited from among volunteers who provided written informed consent after receiving a full explanation of the study. The subjects were screened based on the inclusion and exclusion criteria. Inclusion criteria were as follows: 1 BMI 25 to 30 kg/m 2 , 2 waist circumference ≥ 85 cm, 3 age 35 to 65 years, and 4 ability to provide informed consent. Exclusion criteria were as follows: 1 presence of liver, kidney, and cardiovascular disease; respiratory, endocrine, metabolic, nervous system, or cognitive disorders; and diabetes mellitus or other diseases, 2 surgery within 2 months before the trial, 3 taking medications for hyperglycemia, lipidemia, or hypertension, 4 taking supplements or foods authorized by the government as specific health treatments, 5 unpleasant feeling during blood drawing, 6 donated 200 mL or more blood within 1 month before the trial, 7 changes in weight of 2 kg or more within 1 month before the trial, 8 shift worker, 9 business trip planned for 10 consecutive days or more, 10 not accustomed to the test diet, 11 allergies against any constituents in the test diet, 12 unable to conform to the alcohol limitation, 13 unable to conform to recording daily life using the prescribed format, 14 unable to maintain a record of the daily diet, 15 unable to comply with advice, 16 planned pregnancy or lactation during the trial, and 17 determined to be unqualified by the physician in charge.
The sample size was estimated based on a previous study performed by Takei et al. 20 . In their study, a significant difference between TAG and ALA-DAG was observed in 22 participants in each group under similar conditions characteristics of the subjects, duration of the intervention, and ALA-DAG dosage 20 . Therefore, the sample size for efficacy was estimated to be at least 22 subjects. The target sample size was set to 85 subjects in each group as a full analysis set FAS sufficient for investigating the safety aspects of ALA-DAG. One hundred eighty-four obese subjects were recruited and allocated to each group using computer-generated random numbers.
Test diet
The ALA-DAG was prepared according to the method reported by Watanabe et al. 21 from flaxseed oil Summit
Oil Corporation, Chiba, Japan and rapeseed oil The Nisshin OilliO Group, Ltd., Tokyo, Japan using equipment owned by Kao Corporation Tokyo, Japan . DAG-bound ALA comprised 0.9 g as fatty acid weight per 2.5 g ALA-DAG. The control TAG was rapeseed oil The Nisshin OilliO Group, Ltd. . The compositions of the TAG and ALA-DAG are shown in Table 1 . The prepared ALA-DAG was mixed with rapeseed oil, antioxidants, and emulsifying agents to produce a cooking oil. A test shortbread was prepared to ensure accurate and certain ingestion of ALA-DAG or TAG, and contained hard flour, soft flour, superfine sugar, salt, egg, pullulan, and water in addition to the cooking oil. The test shortbread has 291.1 kcal protein 7.5 , fat 39.3 , carbohydrate 53.2 as energy per serving 2.5 g ALA or TAG in 60 g shortbread . The test shortbread was individually packaged and the content of TAG or ALA-DAG could not be distinguished by its appearance, taste, or odor.
Measurements
VFA was measured using the EW-FA90 Panasonic Corporation, Osaka, Japan , which analyzes VFA based on impedance with no X-ray exposure and is highly correlated with the computed tomography method 22 . The Japanese Government authorized EW-FA90 as a medical device No. 22500BZX00522000 December 6, 2013. Urinary measurements, hematologic parameters, and blood biochemistries were analyzed by SRL Inc. Tokyo, Japan
Statistics
Analyses were performed with SPSS version 19 software IBM Inc. Tokyo, Japan . The FAS included data from all subjects who completed at least 12 wk of the study and complied with the study protocol by consuming ≥ 80 of the test shortbread. Primary outcome was change in VFA. Secondary outcomes were body weight, waist circumference, and safety parameters. Significant differences in the primary and secondary outcomes between groups were assessed based on changes from the baseline to the 12-wk time-point by Student s t test when the data were normally distributed. When the data were not normally distributed, the data were log-transformed prior to analysis. When the data could not be log-transformed, a Mann-Whitney U test was performed. The incidence of adverse events was assessed with Fisher s exact test two-tailed in the intention to treat samples, including data from all subjects who had at least one clinic visit after consuming at least one test shortbread. A P value of less than 0.05 was considered statistically significant. Data are shown as mean standard deviation SD .
RESULTS

Subjects and characteristics
Of the 288 individuals who underwent screening, 184 were randomly assigned to 1 of the 2 treatment groups. Of those 184 subjects, 92 were in the TAG group and 92 were in the ALA-DAG group. In the TAG group, 3 subjects did not complete the study; 1 subject did not show up for any of the scheduled test days, and 2 withdrew because of serious adverse events before the 4-wk time-point, as described in the safety section. In the ALA-DAG group, 4 subjects did not complete the study; 3 withdrew their consent before the treatment, and 1 did not show up the 12-wk time-point because of upper respiratory infection and withdrew. Therefore, the FAS sample comprised 89 subjects male/female, 35/54; age, 50 7 y; BMI, 27.1 1.4 kg/m 2 , in the TAG group and 88 male/female, 34/54; age, 50 8 y; BMI, 27.1 1.5 kg/m 2 in the ALA-DAG group.
None of the parameters measured at baseline differed significantly between groups.
Daily habit
The consumption rates of the test shortbread were 99.4 0.2 in the TAG group and 99.5 0.1 in the ALA-DAG group, with no significant difference between groups. The subjects recorded their diets for 3 days before each clinic visit, and a registered dietician analyzed the dietary records based on the Food Composition Table Kagawa Nutrition University Publishing Division . Although the energy, protein, fat, and carbohydrate intake did not differ significantly between the groups throughout the study, the energy and fat intake increased by 200 kcal and 10 g, respectively, from the baseline to the treatment period in both groups. Physical activity was measured using a pedometer. The mean number of steps from the 4-wk timepoint to the 8-wk time-point was significantly lower in the ALA-DAG group compared with the TAG group, although no significant differences were detected at the other timepoints. The dietary and step records in the FAS are shown in Table 2 .
Primary outcome: VFA
Changes in VFA at 12-wk from baseline were significantly lower in the ALA-DAG group than in the TAG group, both in the FAS samples and in subjects with VFA ≥ 140 cm 2 who were in the top quartile Table 3 . A greater effect was found in the subjects with VFA ≥ 140 cm 2 Table 3 and the reduction of VFA was significantly correlated with the baseline VFA in the ALA-DAG group, but not in the TAG Fig. 1 .
Secondary outcomes: body-composition variables
In the FAS, changes in body weight and waist circumference were significantly lower in the ALA-DAG group compared with the TAG group Table 4 . Changes in VFA were significantly correlated with changes in body weight and waist circumference in the ALA-DAG group Fig. 2 . 
Safety
Of 91 intention-to-treat samples in the TAG group and 90 in the ALA-DAG group, adverse events occurred 57 subjects in the TAG group and 49 subjects in the ALA-DAG group. The most common adverse events were upper respiratory infections TAG and ALA-DAG; n s 21 and 21, respectively , gastrointestinal complaints n s 14 and 8, respectively , and headaches n s 8 and 8, respectively . Other adverse events considered to be mild or moderate were tiredness, listlessness, skin problems, backache, and muscle ache n s 12 and 12, respectively . Only two subjects in the TAG group reported serious adverse events during the treatments. In the TAG group, breast cancer was detected in one subject before the 4-wk time-point and uterine myoma was detected in another patient before the 4-wk time-point. Both cases with serious adverse events dropped out of the study, but no cause-and-effect relationship between the test shortbread and adverse events was established by the physician in charge. The incidence of adverse events did not differ significantly between the groups.
In general, the incidence of abnormal blood values was similar between groups. Throughout the study, there was no significant difference between groups in heart rate, body temperature, urinary measurements glucose, protein, bilirubin, urobilinogen, ketone body, occult blood reaction, pH, gravity, and sediment , hematologic parameters white 
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blood cell, red blood cell, hemoglobin, hematocrit, mean corpuscular volume, mean cell hemoglobin, mean corpuscular hemoglobin concentration, and platelet , blood electrolytes sodium, potassium, chlorine, calcium, magnesium, phosphorus, and iron , or blood pressure and biochemistries Table 5 .
DISCUSSION
In the present study, VFA in the ALA-DAG group was significantly decreased compared with that in the TAG group Table 3 , consistent with previous animal 23 and human studies 20, 24 . A concomitant decrease in waist circumference was observed in the ALA-DAG group Table 4 . The dietary records indicated that energy and fat intake increased during the treatment in both groups Table 2 , probably due to the additional energy intake from the test shortbread in the regular diet. Additionally, because seasonal variation might affect fat metabolism the study started in the summer and was completed in the winter , body weight increased slightly from the baseline to the 12-wk point in the TAG group Table 4 . Body weight in the ALA-DAG group did not change, however, and the change in body weight differed significantly between groups. Additionally, changes in the VFA and body weight Fig. 2 were significantly correlated in the ALA-DAG group, suggesting that ALA-DAG suppressed weight gain, possibly via a reduction in VFA. A potential mechanism, as suggested by Katsuragi et al. 24 , is that resting metabolic rate is enhanced after a 6-wk period of repeated ALA-DAG consumption in humans and dietary fat oxidation is increased after a 3-wk period of repeated ALA-DAG consumption in rats 25 . These effects were thought to be due to the stimulated fat metabolism involved in the enzyme activities and the expression of genes related to beta-oxidation and thermogenesis in the small intestine 26 and liver 27 . Our observation indicated that the reduction in VFA induced by ALA-DAG was greater in subjects with a higher baseline VFA. Thus, ALA-DAG is expected to protect against an excessive accumulation of VFA. Increasing VFA is strongly associated with the clustering of metabolic risk factors, such as hypertension, high blood glucose, high triglyceride, and low high-density lipoprotein 3 . Blood lipids and sugar metabolism, however, were not significantly affected in the ALA-DAG group in the present study. A possible explanation for this finding is the increased energy and fat intake from the test shortbread, as mentioned above. Another possible explanation is that the subjects had normal metabolic parameters Table 5 . Therefore, the effects of ALA-DAG on blood metabolic parameters require further exploration. Additional trials are needed to investigate the effect of ALA-DAG on metabolic syndrome in obese subjects with abnormal metabolic factors. Taste, odor, and appearance are similar between ALA-DAG and rapeseed-derived TAG. Compliance with the study protocol in consuming the test shortbread was very high 99.5 0.1 . Adverse events and safety parameters Table 5 Changes in blood pressure and biochemistries in the FAS. Data are mean SD. No significant differences were observed between groups. Abbreviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, γ-glutamyltransferase; ALP, alkaline phosphatase; LDH, lactase dehydrogenase. Table 5 Continued.
did not differ significantly between the groups, suggesting that ALA-DAG could be easily incorporated in a regular diet as a useful food constituent against visceral fat accumulation without safety or flavor concerns.
CONCLUSION
ALA-DAG could be useful for reducing VFA and concomitantly suppressing weight gain with no side effects.
LIMITATIONS
Although the dietary records did not differ significantly between the groups, energy and fat intake were increased in both groups. Therefore, this study was not performed in a calorie-controlled condition. Physical activity measured with a pedometer at the 4-wk point was significantly lower in the ALA-DAG group than in the TAG group, which could have affected the primary outcome. Because subcutaneous fat area was not measured, the effect of ALA-DAG on it could not be discussed.
